ANTX NASDAQ
AN2 Therapeutics, Inc.
1W: +2.7%
1M: -4.1%
3M: +13.6%
YTD: +344.1%
1Y: +348.2%
3Y: -36.4%
$4.70
-0.23 (-4.67%)
Weekly Expected Move ±6.7%
$4
$5
$5
$5
$6
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$169.3M
52W Range1-6.91
Volume92,907
Avg Volume298,637
Beta-0.99
Dividend$2.62
Analyst Ratings
Company Info
CEOEric E. Easom
Employees21
SectorHealthcare
IndustryBiotechnology
IPO Date2022-03-25
Websitean2therapeutics.com
1800 El Camino Real
Menlo Park, CA 94027
US
Menlo Park, CA 94027
US
650-331-9090
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Latest News
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Aziz Kabeer | A-Award | 2,852 | — | 2026-07-10 |
| Marks Gilbert Lynn | A-Award | 2,789 | — | 2026-07-10 |
| Martin Patricia A. | A-Award | 766 | — | 2026-07-10 |
| Eizen Joshua M | S-Sale | 5,945 | $4.17 | 2026-07-08 |
| Williams Sarah Joann | S-Sale | 265 | $4.43 | 2026-05-29 |